Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HM201 in Healthy Subjects
NCT05088369Phase 1Completed
- Sponsor
- Syneos Health
- Start
- Nov 2021
- Primary completion
- Dec 2022
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HM201 in ulcerative colitis (UC) and Crohn's disease (4 arms), sponsored by Syneos Health. Primary endpoint: Number and percentage of treatment-emergent adverse event, serious adverse event and discontinuation. Started Nov 2021; status: completed.
02
Drugs
HM201
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT05088369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05088369.